Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05769959 · ClinicalTrials.gov registry record · Phase 1
Study of RO7515629 in Participants With HLA-G Positive Solid Tumors
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT05769959: Clinical Trial Phase 1 study, sponsored by Hoffmann-La Roche.
NCT05769959 is a Phase 1 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05769959, a Phase 1 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, immune response and preliminary anti-tumor activity of RO7515629 alone in participants with advanced or metastatic solid tumors expressing human leukocyte antigen G (HLA-G).
Interventions
- DRUG tocilizumab
- DRUG RO7515629
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2023-06-15 |
| Est. Completion | 2024-03-19 |
| Phase | Phase 1 |
Why NCT05769959 stopped before completion
NCT05769959 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which tocilizumab is the first listed.
NCT05769959 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05769959 about?
NCT05769959 is a clinical study titled "Study of RO7515629 in Participants With HLA-G Positive Solid Tumors". The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, immune response and preliminary anti-tumor activity of RO7515629 alone in participants with advanced or metastatic solid tumors expressing human leukocyte antigen G (HLA-G).
What is the current status of trial NCT05769959?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2023-06-15. Estimated completion is 2024-03-19.
What interventions are being tested in trial NCT05769959?
The interventions under investigation include: tocilizumab (DRUG), RO7515629 (DRUG).
Who is sponsoring clinical trial NCT05769959?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05769959's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI